STOCK TITAN
  1. Home
  2. News
  3. MNK

Mallinckrodt Plc - MNK STOCK NEWS

Welcome to our dedicated news page for Mallinckrodt Plc (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mallinckrodt Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mallinckrodt Plc's position in the market.

News
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
Rhea-AI Summary
Mallinckrodt plc reports strong financial results for fiscal year 2023, exceeding high-end guidance on net sales and adjusted EBITDA. Key milestones achieved in Specialty Brands with successful product launches and FDA approvals. New board members appointed. Financial guidance for 2024 provided. Detailed analysis of positive and negative aspects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients
Rhea-AI Summary
Mallinckrodt plc announces positive findings from a retrospective analysis on Acthar Gel treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis. The study indicates similar health status improvement and symptom reduction in both groups, suggesting Acthar Gel as a viable treatment option for sarcoidosis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
Rhea-AI Summary
Mallinckrodt plc appoints Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands. Mr. O'Neill brings over 25 years of experience in manufacturing operations and will lead key initiatives to enhance supply performance and launch new products. Mallinckrodt aims for long-term growth under his leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Rhea-AI Summary
Mallinckrodt plc receives FDA approval for Acthar Gel Single-Dose Pre-filled SelfJect Injector, a new delivery device for patients with inflammatory and autoimmune conditions. The device aims to simplify Acthar Gel administration, enhancing patient control. The product is set to launch in the U.S. in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Mallinckrodt Announces Board of Directors and Leadership Updates
Rhea-AI Summary
Mallinckrodt plc announced the addition of four seasoned professionals to its Board of Directors, including Paul Bisaro as Board Chair. Siggi Olafsson will continue as President, CEO, and Board Member. The company aims to strengthen its leadership team and continue to deliver for its patients and public health needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress
Rhea-AI Summary
Mallinckrodt plc announced the presentation of findings from a post hoc analysis of the Phase 3 CONFIRM clinical trial, showing the therapeutic effect of TERLIVAZ in adult patients with hepatorenal syndrome and alcoholic hepatitis. The analysis found that the incidence of verified HRS reversal was significantly higher in patients treated with TERLIVAZ vs. placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting
Rhea-AI Summary
Mallinckrodt plc announced that three scientific abstracts evaluating treatment with TERLIVAZ for adults with hepatorenal syndrome (HRS) will be presented at the American Society of Nephrology Kidney Week 2023 Scientific Meeting. TERLIVAZ is the first FDA-approved product indicated to improve kidney function in adults with HRS. The abstracts will explore the impact of TERLIVAZ on patient care, key HRS endpoints, patient comorbidity, and the role of TERLIVAZ in HRS reversal. The studies are sponsored by Mallinckrodt Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
conferences
-
News
Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023
Rhea-AI Summary
Mallinckrodt plc shared findings from health economics research on Acthar Gel for patients with advanced symptomatic sarcoidosis and nephrotic syndrome. The cost-effectiveness analysis showed that Acthar Gel resulted in an incremental cost-effectiveness ratio (ICER) of $134,796 per quality-adjusted life-year (QALY) and $39,179 per QALY over two and three years, respectively. From a societal perspective, Acthar versus standard of care resulted in an ICER of $117,622 per QALY over two years and $21,967 per QALY over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
News
Buxton Helmsley Issues Statement on Mallinckrodt plc. Bankruptcy Filing and Disclosures Revealing Apparently Concealed Intangible Asset Depreciation Expenses
Rhea-AI Summary
Mallinckrodt Plc. files for Chapter 11 bankruptcy protection, revealing nearly $1 billion in intangible asset depreciation expenses that were allegedly concealed. Current shareholders are set to receive no recovery as their equity interests will be wiped out. Company's insiders remain silent on allegations of accounting and securities fraud. BHG's allegations may have been vindicated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.93%
Tags
none
News
Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations
Rhea-AI Summary
Mallinckrodt receives approvals for Chapter 11 petitions, enabling normal operations and payment of vendors and suppliers. Restructuring plan to reduce total funded debt by $1.9 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.71%
Tags
none
Stock MNK logo
Mallinckrodt Plc

NYSE:MNK

MNK Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MNK Stock Data

4.52M
5.72M
10.09%
96.64%
13.46%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
College Business Technology Park Cruiserath

About MNK

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit